Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients

Autor: Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedl, DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC

Publikováno v: International Journal of Nanomedicine, Vol 2012, Iss default, Pp 5555-5564 (2012)

Huali Wu,1 Ramesh K Ramanathan,2 Beth A Zamboni,3 Sandra Strychor,4 Suresh Ramalingam,5 Robert P Edwards,4 David M Friedland,4 Ronald G Stoller,4 Chandra P Belani,4 Lauren J Maruca,4 Yung-Jue Bang,6 William C Zamboni11UNC Eshelman School of Pharmacy,

Externí odkaz: https://doaj.org/article/aabcd19fae254a208e2df1d1184be083

Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes

Autor: Coleman, CN, Stoller, RG, Drake, JC, Chabner, BA

Publikováno v: Blood; November 1975, Vol. 46 Issue: 5 p791-803, 13p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).

Autor: Malhotra MK; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Pahuja S; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA., Appleman LJ; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Ding F; Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lin Y; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Tawbi HA; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Stoller RG; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lee JJ; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Belani CP; Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.; Center for Cancer Research, National Cancer Institute, Bethesda, USA., Giranda VL; AbbVie Laboratories, North Chicago, IL, USA., Shepherd SP; AbbVie Laboratories, North Chicago, IL, USA., Emens LA; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Ivy SP; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Chu E; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, Montefiore Einstein Cancer Center, Bronx, NY, USA., Beumer JH; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA. beumerj@gmail.com.; UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA. beumerj@gmail.com., Puhalla S; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. puhallasl@upmc.edu.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. puhallasl@upmc.edu.; UPMC Magee Women's Hospital, 300 Halket Street, Pittsburgh, PA, 15213, USA. puhallasl@upmc.edu.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Apr; Vol. 198 (3), pp. 487-498. Date of Electronic Publication: 2023 Feb 28.

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Autor: Boone BA; Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N

Publikováno v: Journal of surgical oncology [J Surg Oncol] 2013 Sep; Vol. 108 (4), pp. 236-41.